Chromatin landscape and endocrine response in breast cancer

Epigenomics

Volumn 4, Issue 6, 2012, Pages 675-683

  Magnani, Luca ^a   Brunelle, Mylène ^b   Gévry, Nicolas ^b   Lupien, Mathieu ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

breast cancer; ChIP seq; chromatin; chromatin landscape; DNA methylation; endocrine therapy resistance; epigenetic; epigenomic; estrogen receptor; histone modification; hormonal therapy; pioneer factors

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR PBX1;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHROMATIN STRUCTURE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GENOMICS; HORMONE RESPONSE; HUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS;

EID: 84871451101     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.64     Document Type: Review

References (80)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
3. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346-352 (2012).
4. Carroll JS, Liu XS, Brodsky AS et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122(1), 33-43 (2005). (Pubitemid 40977938)
5. Lupien M, Eeckhoute J, Meyer CA et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132(6), 958-970 (2008). (Pubitemid 351391952)
6. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 genomic pioneer function drives ERa signaling underlying progression in breast cancer. PLoS Genet. 7(11), e1002368 (2011).
7. Tan SK, Lin ZH, Chang CW et al. AP-2g regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J. 30(13), 2569-2581 (2011).
8. Holmes KA, Hurtado A, Brown GD et al. Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc. Natl Acad. Sci. USA 109(8), 2748-2753 (2011).
9. Eeckhoute J, Lupien M, Meyer CA et al. Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. Genome Res. 19(3), 372-380 (2009).
10. He HH, Meyer CA, Shin H et al. Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 42(4), 343-347 (2010).
11. Fullwood MJ, Liu MH, Pan YF et al. An oestrogen-receptor-a-bound human chromatin interactome. Nature 462(7269), 58-64 (2009).
12. Györffy B, Lanczky A, Eklund AC et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123(3), 725-731 (2010).
13. Li G, Ruan X, Auerbach RK et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148(1-2), 84-98 (2012).
14. Ali S, Buluwela L, Coombes RC. Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu. Rev. Med. 62, 217-232 (2011).
15. Orlando L, Schiavone P, Fedele P et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat. Rev. 36(Suppl. 3), S67-S71 (2010).
16. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2(3), 205-213 (2003). (Pubitemid 37361665)
17. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J. Clin. Oncol. 26(5), 798-805 (2008). (Pubitemid 351264393)
18. Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12(4), 721-747 (2005). (Pubitemid 41815773)
19. Johnston SJ, Cheung KL. Fulvestrant -a novel endocrine therapy for breast cancer. Curr. Med. Chem. 17(10), 902-914 (2010).
20. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11(4), 643-658 (2004). (Pubitemid 40065543)
21. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9(6), 465-476 (2008). (Pubitemid 351693975)
22. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J. Mammary Gland Biol. Neoplasia 3(1), 85-94 (1998). (Pubitemid 128513222)
23. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54(10), 2552-2555 (1994). (Pubitemid 24173735)
24. Yoshida T, Eguchi H, Nakachi K et al. Distinct mechanisms of loss of estrogen receptor a gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21(12), 2193-2201 (2000). (Pubitemid 32049225)
25. Parrella P, Poeta ML, Gallo AP et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin. Cancer Res. 10(16), 5349-5354 (2004). (Pubitemid 39100470)
26. Jing MX, Mao XY, Li C, Wei J, Liu C, Jin F. Estrogen receptor-a promoter methylation in sporadic basal-like breast cancer of Chinese women. Tumour Biol. 32(4), 713-719 (2011).
27. Vesuna F, Lisok A, Kimble B et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-a. Oncogene 31(27), 3223-3234 (2011).
28. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-a (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2(5), 552-556 (2003).
29. Leu YW, Yan PS, Fan M et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res. 64(22), 8184-8192 (2004). (Pubitemid 39491754)
30. Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene 27(29), 4075-4085 (2008). (Pubitemid 351931987)
31. Mack GS. To selectivity and beyond. Nat. Biotechnol. 28(12), 1259-1266 (2010).
32. Zhang W, Wang L, Fan Q et al. Arsenic trioxide re-sensitizes ERa-negative breast cancer cells to endocrine therapy by restoring ERa expression in vitro and in vivo. Oncol. Rep. 26(3), 621-628 (2011).
33. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66(12), 6370-6378 (2006).
34. Fan M, Yan PS, Hartman-Frey C et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66(24), 11954-11966 (2006). (Pubitemid 46094209)
35. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9(9), 631-643 (2009).
36. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
37. Lupien M, Meyer CA, Bailey ST et al. Growth factor stimulation induces a distinct ER(a) cistrome underlying breast cancer endocrine resistance. Genes Dev. 24(19), 2219-2227 (2010).
38. Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389-393 (2012).
39. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389(6648), 251-260 (1997). (Pubitemid 27406632)
40. Heintzman ND, Stuart RK, Hon G et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39(3), 311-318 (2007). (Pubitemid 46328487)
41. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 28(8), 817-825 (2010).
42. Ernst J, Kheradpour P, Mikkelsen TS et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473(7345), 43-49 (2011).
43. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470(7333), 279-283 (2011).
44. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2), 315-326 (2006).
45. Heintzman ND, Hon GC, Hawkins RD et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459(7243), 108-112 (2009).
46. Wang Q, Li W, Zhang Y et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2), 245-256 (2009).
47. Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1), 69-80 (2010).
48. Akhtar-Zaidi B, Cowper-Sal Lari R, Corradin O et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336(6082), 736-739 (2012).
49. Magnani L, Zhang X, Stoeck A et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Presented at: Epigenetic Regulation: from Mechanism to Intervention. London, UK, 20-22 June 2012.
50. Allis CD, Berger SL, Cote J et al. New nomenclature for chromatin-modifying enzymes. Cell 131(4), 633-636 (2007). (Pubitemid 350089969)
51. Di Marcotullio L, Canettieri G, Infante P, Greco A, Gulino A. Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim. Biophys. Acta 1815(2), 241-252 (2011).
52. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360), 298-303 (2011).
53. van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009).
54. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11(5), 384-400 (2012).
55. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-a and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71(5), 1893-1903 (2011).
56. Shi Y, Lan F, Matson C et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941-953 (2004). (Pubitemid 40037608)
57. Schenk T, Chen WC, Göllner S et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18(4), 605-611 (2012).
58. Lim S, Janzer A, Becker A et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31(3), 512-520 (2010).
59. Talbert PB, Henikoff S. Histone variants -ancient wrap artists of the epigenome. Nat. Rev. Mol. Cell Biol. 11(4), 264-275 (2010).
60. Jin C, Zang C, Wei G et al. H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat. Genet. 41(8), 941-945 (2009).
61. Hua S, Kallen CB, Dhar R et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 4, 188 (2008).
62. Svotelis A, Gevry N, Grondin G, Gaudreau L. H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle 9(2), 364-370 (2010).
63. Gevry N, Hardy S, Jacques PE et al. Histone H2A.Z is essential for estrogen receptor signaling. Genes Dev. 23(13), 1522-1533 (2009).
64. Sérandour A A, Avner S, Percevault F et al. Epigenetic switch involved in activation of pioneer factor FOX A1-dependent enhancers. Genome Res. 21(4), 555-565 (2011).
65. Wang D, Garcia-Bassets I, Benner C et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474(7351), 390-394 (2011).
66. Abukhdeir AM, Vitolo MI, Argani P. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc. Natl Acad. Sci. USA 105(1), 288-293 (2008).
67. Gévry N, Chan HM, Laflamme L, Livingston DM, Gaudreau L. p21 transcription is regulated by differential localization of histone H2A.Z. Genes Dev. 21(15), 1869-1881 (2007). (Pubitemid 47204927)
68. Magnani L, Eeckhoute J, Lupien M. Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet. 27(11), 465-474 (2011).
69. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 25(21), 2227-2241 (2011).
70. Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 12(6), 381-385 (2012).
71. Badve S, Turbin D, Thorat MA et al. FOXA1 expression in breast cancer -correlation with luminal subtype A and survival. Clin. Cancer Res. 13(15 Pt 1), 4415-4421 (2007). (Pubitemid 47219708)
72. Mehta RJ, Jain RK, Leung S et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res. Treat. 131(3), 881-890 (2011).
73. Bernstein BE, Stamatoyannopoulos JA, Costello JF et al. The NIH roadmap epigenomics mapping consortium. Nat. Biotechnol. 28(10), 1045-1048 (2010).
74. American Association for Cancer Research Human Epigenome Task Force, European Union, Network of Excellence, Scientific Advisory Board. Moving AHEAD with an International Human Epigenome Project. Nature 454(7205), 711-715 (2008).
75. De Santa F, Barozzi I, Mietton F et al. A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol. 8(5), e1000384 (2010).
76. Wang KC, Yang YW, Liu B et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472(7341), 120-124 (2011).
77. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071-1076 (2010).
78. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3z and promotes breast cancer cell survival and endocrine resistance. Oncogene 31(1), 39-47 (2012).
79. Shibahara Y, Miki Y, Onodera Y et al. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J. Pathol. 227(3), 357-366 (2012).
80. Lieberman-Aiden E, van Berkum NL, Williams L et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326(5950), 289-293 (2009)